Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

Is Carboplatin recalled?

Not under an active recall. Carboplatin was recalled 8 times in the past — all now closed. Most recent: Jun 12, 2019.

Most common reason: Failed specification (3 of these recalls)

Recalls are matched by product description. A recall usually affects specific lots, not every package of Carboplatin. “Active” means an FDA recall is still ongoing; “closed” means it was terminated or completed. Checked against openFDA on Oct 10, 2026.

Carboplatin recalls on record

none so far in 2026; 8 on record, newest first
Class II · Moderate risk

Carboplatin active pharmaceutical ingredient packaged in varying…

Penicillin Cross Contamination: All lots of all products repackaged between 01/05/12 through 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.

Terminated Cross-contamination Attix Pharmaceuticals D-562-2015
Class II · Moderate risk

CARBOplatin Injection

Lack of Assurance of Sterility: The required reduction of endotoxin was not met during the annual revalidation of the vial washer.

Terminated Sterility / contamination Teva Pharmaceuticals USA, Inc. NDC 0703-3249-11 D-928-2013
Class I · High risk

Carboplatin Injection

Crystallization: Product is being recalled due to visible particulates identified during a retain sample inspection. Findings have identified the particles as Carboplatin crystals.

Completed Failed specification Hospira Inc. NDC 61703-339-50 D-154-2013
Class I · High risk

Carboplatin Injection

Crystallization: Product is being recalled due to visible particulates identified during a retain sample inspection. Findings have identified the particles as Carboplatin crystals.

Completed Failed specification Hospira Inc. NDC 61703-339-56 D-153-2013
Class III · Low risk

Carboplatin Injection

Failed PH specification: The lots of Carboplatin Injection were manufactured from Carboplatin API lots which trended out of specification low pH.

Terminated Failed specification Hospira Inc. NDC 61703-339-18 D-1648-2012
Class II · Moderate risk

Carboplatin Injection

The affected lots of Carboplatin Injection, Cytarabine Injection, Methotrexate Injection, USP, and Paclitaxel Injection are beig recalled due to visible particles embedded in the glass located at the neck of the vial. There may be the potential for product to come into contact with the embedded particles and the particles may become dislodged into the solution.

Terminated Particulate / foreign matter Hospira Inc. NDC 61703-339-50 D-1679-2012